DArecca James 4

What Happened
DArecca James, Chief Financial Officer of Haemonetics Corporation (HAE), received an award of 29,312 restricted stock units (RSUs) on May 15, 2026. In connection with vesting of certain previously reported RSUs, 2,505 shares were withheld (disposed) to satisfy tax obligations at an indicated price of $56.29 per share, generating $141,006. The new RSUs are granted under Haemonetics’ 2019 Long-Term Incentive Compensation Plan and are contingent rights to receive one share per RSU when they vest.

Key Details

• Transaction dates: May 15, 2026 (award grant and tax-withholding disposition).
• Award: 29,312 RSUs granted (code A). No immediate cash value reported for the grant on the Form 4.
• Tax withholding: 2,505 shares withheld (code F) at $56.29/share = $141,006 to cover tax liabilities tied to vesting of previously reported RSUs.
• Vesting schedule: RSUs vest in three annual installments — 40% on first anniversary, 40% on second, 20% on third (per footnote). Each RSU equals one share when vested.
• Shares owned after transaction: not specified in this filing.
• Filing timeliness: Report filed May 19, 2026 for transactions dated May 15, 2026 — within the required two business-day reporting window (timely).
• Footnotes: withheld shares were used solely for tax obligations; the reported award includes unvested RSUs previously reported.

Context
RSU grants are compensation and are contingent on future vesting; they are not the same as an open-market purchase (which can be a stronger bullish signal). Withholding shares to satisfy taxes is a routine administrative step and does not necessarily indicate an intent to sell additional shares.